Ohta et al.'s study 51 showed that KEAP1 inactivation mutations occur in lung cancer and HCC, and activation of genes that inhibit NRF2 inhibition of Keap1 in lung, Skin, and liver cancer 52. This evidence concerns the gene KEAP1 and lung carcinoma.